Keating Investment Counselors Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 50.0% during the second quarter, Holdings Channel reports. The institutional investor owned 22,187 shares of the biopharmaceutical company’s stock after selling 22,213 shares during the period. Keating Investment Counselors Inc.’s holdings in Pfizer were worth $781,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of PFE. Stelac Advisory Services LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $110,000. Commonwealth Financial Services LLC raised its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares during the period. Catamount Wealth Management raised its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. raised its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Finally, Jag Capital Management LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $202,000. Institutional investors own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 1.65% on Friday, hitting $33.87. 27,809,992 shares of the company were exchanged. The stock’s 50-day moving average price is $34.51 and its 200-day moving average price is $34.02. The stock has a market capitalization of $205.44 billion, a P/E ratio of 30.03 and a beta of 0.87. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. Pfizer’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.56 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.54%. Pfizer’s dividend payout ratio is presently 95.24%.
Several brokerages recently issued reports on PFE. Bank of America Corp. reiterated a “buy” rating and issued a $40.00 price target on shares of Pfizer in a research note on Tuesday. Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a research note on Monday. Jefferies Group decreased their price target on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, September 13th. Argus reissued a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Sunday, August 28th. Finally, Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 23rd. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.